This site uses optional cookies which are currently not set, but will be if you visit another page. Find out more about the cookies we use

Bionow Members succeed in RGF Round 3

22 October 2012

Details from the successful applicants official press releases are below with the full releaases available via the downloads to the right.

AstraZeneca awarded £5m for BioScience cluster at Alderley Park

‘AstraZeneca welcomes the news today that we have been successful in our initial application for £5 million investment from the UK Department for Business, Innovation and Skills’ Regional Growth Fund.

The pledged commitment of the Regional Growth Fund enables us to further explore the potential of developing a BioScience cluster on our Alderley Park R&D site. If successful, this venture would create a unique hub for pharmaceutical innovation and biotech enterprise in the North West and represent a positive example of progress for the UK’s life sciences sector.’

The focus of the venture is to build on AstraZeneca’s world-class pharmaceutical R&D site by providing a highly supportive environment to spin-out, nurture and attract innovative biomedical enterprises. The companies located on the site would have facilitated access to AstraZeneca’s state-of-the-art facilities, know-how and human capital.

“This initiative reflects the changing face of pharmaceutical R&D and our focus on collaboration to access and develop the best science and technology”, said Martin Mackay, President of R&D at AstraZeneca. “Alderley Park is a site of critical importance to our global R&D organisation. By combining our capabilities with those of our partners and other enterprises, we aim to create a hub of scientific innovation with the potential to discover the medicines that people will need in years to come.”

The development will be made possible through the Regional Growth Fund grant, investment and support from the participating partners and the commitment of land and facilities from AstraZeneca.

Alderley Park project leader, Dr Chris Doherty, said: “We’re very excited about the potential of this initiative and the prospects for a dynamic science cluster in the North West. A number of people have been working hard behind the scenes to get us to this stage. In particular, we are grateful for the support of Rt Hon George Osborne and David Rutley MP, as well as Cheshire East Council, University of Manchester, Greater Manchester and Cheshire & Warrington Local Enterprise Partnerships and Bionow.”

Novartis Global Centre of Excellence for influenza vaccine manufacture.

The Novartis Vaccines and Diagnostics Limited site in Liverpool has been selected for possible regional growth funding from the Department of Business Innovations and Skills (BIS).

If successful, the award will be used for infrastructure and capability improvements, strengthening the site as a Novartis Global Centre of Excellence for influenza vaccine manufacture.

Novartis welcomes the Government’s investment in life sciences. This is a positive step in bringing investment into Liverpool, and in particular the Speke area, which is located in the North West biotechnology hub.

Eli Lilly, Speke awarded £3m to support animal health

Eli Lilly and Company Ltd has been awarded £3m by the Government’s Regional Growth Fund to support their £30m bid to expand manufacturing operations in Liverpool. Lilly has been manufacturing medicines in Liverpool since 1963 and currently has approximately 650 staff at the site. The company, headquartered in Indiana, USA, are in the final stages of deciding where to manufacture an innovative new animal health medicine. The management team at the Speke site believe the Government’s support is crucial in its bid to win the investment, which would create a significant number of jobs on the site.

Peter Troutt, General Manager at the Eli Lilly and Company Ltd Speke site commented:

‘The Speke site is up against some tough competition to win the right to manufacture this innovative new medicine. We believe this support from the Government will help tip the balance in our favour. This is a challenging time for UK life sciences and we are delighted the Government has recognised the importance of the sector in promoting growth and jobs.”

Redx Pharma awarded £4.7 million grant for new spin out

Early stage drug development company Redx Pharma has been awarded a £4.7 million grant from the UK Government's Regional Growth Fund (RGF) to support the launch of a new £10.8 million research and development centre focused on anti-viral and anti-bacterial drugs.

The funding will enable the establishment of a new subsidiary, Redx Anti-Infectives Ltd, which will create 119 high value science jobs, based in Liverpool. The posts will be within chemistry, biochemistry and analytical testing. A further 28 specialist jobs are expected to be created within the wider supply chain.

Redx Anti-Infectives will begin operations in April 2013. The funds, which are subject to a due diligence process, will support an initial two-year industrial research phase of chemistry, biochemistry and analytical testing. The new R&D venture will focus on developing drugs to combat resistance to antibiotics and new medicines to tackle viral infections. These include developing anti-infective drugs tackling hard to treat infections, including the growing threat of drug resistant superbugs like MRSA, as well as conditions such as influenza, Hepatitis C and HIV.

Sci-Tech Daresbury awarded £10m

Sci-Tech Daresbury has been awarded £10m to fund its ambitious expansion plans.

John Downes, chief executive of property company Langtree, one of the three partners of Sci-Tech Daresbury, said the £10m award was recognition of the strategic role it could play at a regional, national and international level.

He said: “Our vision is to generate some 15,000 skilled jobs at Daresbury over the next 20 years alongside the creation of over 1m square feet of new scientific facilities plus commercial, laboratory and workshop space for science and technology businesses.”